June 29, 2023
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
Launching in the fourth largest aesthetic toxin injectables market in Europe1 is part of the company’s geographic expansion strategy GP…
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
November 14, 2022
Moderna’s biovalent booster candidates meet primary endpoint of superiority against Omicron variants in trai
Moderna said Monday that both of its bivalent Omicron-targeting booster candidates (mRNA-1273.214 and mRNA-1273.222) trigger a superior antibody response compared…
October 14, 2022
Clinical trial labels across the globe – how to manage translations and country specific regulations
In recent years, there has been an industry-wide recognition of the need for speed and agility. Accelerating the trial processes for COVID-19 vaccine candidates required proactive and cooperative efforts from participants at all points in the supply chain. A sense of urgency and an expectation that trials should be completed more quickly and effectively emerged as a result of the realization that a drug can be approved and released to the market in a relatively short period of time. In light of this, improving the speed, accuracy, and agility of clinical trials labeling — and more specifically, the translation of label content — is one of the crucial areas that would help organizations to achieve this.
October 13, 2022
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age
The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of Pfizer BioNTech Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age.
October 13, 2022
Tevogen Bio® Expresses Gratitude for 2023 Nobel Peace Prize Nomination of the Company and its Founding CEO Ryan Saadi in Recognition of its Novel Business Model to Alleviate Health Inequality
Tevogen Bio® and Founding CEO are nominated for the 2023 Nobel Peace Prize by Curtis Patton, PhD, Professor Emeritus, Yale…
October 13, 2022
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions
Company expects to commence patient enrollment and dosing in Q1 2023OCALA, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech…
October 12, 2022
Merck and Moderna take option by Merck for joint development dealing of investigational personalized cancer vaccine
Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement.
October 12, 2022
Inceptua Group, Sentynl Therapeutics Inc team up in Sentynl’s Nulibry availability job
Inceptua Early Access, a business unit of the Inceptua Group, said it has teamed up with Sentynl Therapeutics Inc., a U.S.-based biopharmaceutical company, to make Sentynl’s Nulibry available via an Early Access Program for eligible patients with molybdenum cofactor deficiency (MoCD) Type A.
October 12, 2022
Ginkgo in a deal with Merck
Enzyme biocatalysts can reduce costly synthesis and purification steps, thereby decreasing production costs. Through this collaboration, we aim to optimize…
April 29, 2022
FDA Approves BMS’s Camzyos for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM)
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.